• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 25, 2023 at 10:22: AM
via Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will follow patients for around six years.

article source
 




Top Bottom
Back
Quote